HighTower Advisors’s Acorda Therapeutics ACOR Stock Holding History

HighTower Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-317	Closed	-$900K	–	2407
2017 Q3	$900K	Buy	317 +24	+8%	+$63.2K	0.01%	1144
2017 Q2	$695K	Sell	293 -16	-5%	-$31.7K	0.01%	1218
2017 Q1	$775K	Buy	309 +90	+41%	+$259K	0.01%	1144
2016 Q4	$493K	Buy	219 +17	+8%	+$40.4K	0.01%	1260
2016 Q3	$508K	Sell	202 -3	-1%	-$8.95K	0.01%	1241
2016 Q2	$623K	Buy	205 +38	+23%	+$124K	0.01%	1063
2016 Q1	$526K	Sell	167 -5	-3%	-$20.8K	﹤0.01%	1353
2015 Q4	$885K	Buy	+172	New	+$752K	0.01%	1035

Other funds holding ACOR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HighTower Advisors's ACOR Position: Q4 2017 in Review

HighTower Advisors sold out of Acorda Therapeutics (ACOR) in Q4 2017, closing a stake of 317 shares — an estimated $900K sold.

HighTower Advisors first reported a position in ACOR in Q4 2015 and held it in 8 quarters. The position peaked at $900K in Q3 2017. 150 funds tracked by Wall St. Rank hold ACOR as of Q4 2017.

HighTower Advisors reported no remaining Acorda Therapeutics position as of Q4 2017 after selling out during the quarter.
HighTower Advisors sold 317 Acorda Therapeutics shares in Q4 2017, an estimated $900K.
HighTower Advisors first reported a position in Acorda Therapeutics in Q4 2015 and held it in 8 quarters.
HighTower Advisors's Acorda Therapeutics position peaked at $900K in Q3 2017.
150 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2017.

Based on HighTower Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.